Optimization of Benzothiazole and Thiazole Hydrazones as Inhibitors of Schistosome BCL-2
Limited therapeutic options are available for the treatment of human schistosomiasis caused by the parasitic Schistosoma flatworm. The B cell lymphoma-2 (BCL-2)-regulated apoptotic cell death pathway in schistosomes was recently characterized and shown to share similarities with the intrinsic apoptosis pathway in humans. Here, we exploit structural differences in the human and schistosome BCL-2 (sBCL-2) pro-survival proteins toward a novel treatment strategy for schistosomiasis. The benzothiazole hydrazone scaffold previously employed to target human BCL-XL was repurposed as a starting point to target sBCL-2. We utilized X-ray structural data to inform optimization and then applied a scaffold-hop strategy to identify the 5-carboxamide thiazole hydrazone scaffold (43) with potent sBCL-2 activity (IC50 30 nM). Human BCL-XL potency (IC50 13 nM) was inadvertently preserved during the optimization process. The lead analogues from this study exhibit on-target activity in model fibroblast cell lines dependent on either sBCL-2 or human BCL-XL for survival. Further optimization of the thiazole hydrazone class is required to exhibit activity in schistosomes and enhance the potential of this strategy for treating schistosomiasis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
ACS infectious diseases - 7(2021), 5 vom: 14. Mai, Seite 1143-1163 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nguyen, William [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BCL-2 |
|---|
| Anmerkungen: |
Date Completed 23.06.2021 Date Revised 23.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acsinfecdis.0c00700 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320847659 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320847659 | ||
| 003 | DE-627 | ||
| 005 | 20231225174522.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acsinfecdis.0c00700 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1069.xml |
| 035 | |a (DE-627)NLM320847659 | ||
| 035 | |a (NLM)33523649 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nguyen, William |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Optimization of Benzothiazole and Thiazole Hydrazones as Inhibitors of Schistosome BCL-2 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.06.2021 | ||
| 500 | |a Date Revised 23.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Limited therapeutic options are available for the treatment of human schistosomiasis caused by the parasitic Schistosoma flatworm. The B cell lymphoma-2 (BCL-2)-regulated apoptotic cell death pathway in schistosomes was recently characterized and shown to share similarities with the intrinsic apoptosis pathway in humans. Here, we exploit structural differences in the human and schistosome BCL-2 (sBCL-2) pro-survival proteins toward a novel treatment strategy for schistosomiasis. The benzothiazole hydrazone scaffold previously employed to target human BCL-XL was repurposed as a starting point to target sBCL-2. We utilized X-ray structural data to inform optimization and then applied a scaffold-hop strategy to identify the 5-carboxamide thiazole hydrazone scaffold (43) with potent sBCL-2 activity (IC50 30 nM). Human BCL-XL potency (IC50 13 nM) was inadvertently preserved during the optimization process. The lead analogues from this study exhibit on-target activity in model fibroblast cell lines dependent on either sBCL-2 or human BCL-XL for survival. Further optimization of the thiazole hydrazone class is required to exhibit activity in schistosomes and enhance the potential of this strategy for treating schistosomiasis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a BCL-2 | |
| 650 | 4 | |a BCL-XL | |
| 650 | 4 | |a BH3-mimetic | |
| 650 | 4 | |a benzothiazole | |
| 650 | 4 | |a schistosomiasis | |
| 650 | 7 | |a Benzothiazoles |2 NLM | |
| 650 | 7 | |a Hydrazones |2 NLM | |
| 650 | 7 | |a bcl-X Protein |2 NLM | |
| 700 | 1 | |a Lee, Erinna F |e verfasserin |4 aut | |
| 700 | 1 | |a Evangelista, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Mihwa |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, Tiffany J |e verfasserin |4 aut | |
| 700 | 1 | |a Colman, Peter M |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Nicholas A |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Luke B |e verfasserin |4 aut | |
| 700 | 1 | |a Jarman, Kate E |e verfasserin |4 aut | |
| 700 | 1 | |a Lowes, Kym N |e verfasserin |4 aut | |
| 700 | 1 | |a Haeberli, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Keiser, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Brian J |e verfasserin |4 aut | |
| 700 | 1 | |a Fairlie, W Douglas |e verfasserin |4 aut | |
| 700 | 1 | |a Sleebs, Brad E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACS infectious diseases |d 2015 |g 7(2021), 5 vom: 14. Mai, Seite 1143-1163 |w (DE-627)NLM248280775 |x 2373-8227 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2021 |g number:5 |g day:14 |g month:05 |g pages:1143-1163 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acsinfecdis.0c00700 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2021 |e 5 |b 14 |c 05 |h 1143-1163 | ||